Onno Teng
Hoogleraar Nierziekten, in het bijzonder renale auto-immuunziekten
- Naam
- Prof.dr. Y.K.O. Teng
- Telefoon
- +31 71 526 2214
- y.k.o.teng@lumc.nl
- ORCID iD
- 0000-0001-9920-2195
Onno Teng is hoogleraar Nefrologie met bijzonder aandacht voor renale auto-immuunziekten.
Meer informatie over Onno Teng
Onno Teng is hoogleraar Nefrologie met bijzonder aandacht voor renale auto-immuunziekten.
Hoogleraar Nierziekten, in het bijzonder renale auto-immuunziekten
- Faculteit Geneeskunde
- Divisie 2
- Interne Geneeskunde
- Nierziekten
- Wind, M.; Fierro, J.J.; Bloemenkamp, K.W.M.; Leeuw, K. de; Lely, A.T.; Limper, M.; Sueters, M.; Teng, Y.K.O.; Walter, I.J. & Kooiman, J. (2025), Predictors of pregnancy outcomes in SLE - Authors' reply, The Lancet Rheumatology 7(1): e13-e13.
- Stockfelt, M.; Teng, Y.K.O. & Vital, E.M. (2025), Opportunities and limitations of B cell depletion approaches in SLE, Nature Reviews Rheumatology 21(2): 111-126.
- Leeuwen, J.R. van; Quartuccio, L.; Draibe, J.B.; Gunnarson, I.; Sprangers, B. & Teng, Y.K.O. (2025), Evaluating Avacopan in the Treatment of ANCA-Associated Vasculitis: Design, Development and Positioning of Therapy, Drug Design, Development and Therapy 19.
- Stalman, E.W.; Wieske, L.; Keijser, J.B.D.; Dam, K.P.J. van; Kummer, L.Y.L.; Wilbrink, M.F.; Kempen, Z.L.E. van; Killestein, J.; Volkers, A.G.; Tas, S.W.; Boekel, L.; Wolbink, G.J.; Kooi, A.J. van der; Raaphorst, J.; Löwenberg, M.; Takkenberg, R.B.; D'Haens, G.R.A.M.; Spuls, P.I.; Bekkenk, M.W.; Musters, A.H.; Post, N.F.; Bosma, A.L.; Hilhorst, M.L.; Vegting, Y.; Bemelman, F.J.; Voskuyl, A.E.; Broens, B.; Sanchez, A.P.; Els, C.A.C.M. van; Wit, J. de; Rutgers, A.; Leeuw, K. de; Horváth, B.; Verschuuren, J.J.G.M.; Ruiter, A.M.; Ouwerkerk, L. van; Woude, D. van der; Allaart, R.C.F.; Teng, Y.K.O.; Paassen, P. van; Busch, M.H.; Brusse, E.; Doorn, P.A. van; Baars, A.E.; Hijnen, D.; Schreurs, C.R.G.; Pol, L. van der; Goedee, H.S.; Steenhuis, M.; Keijzer, S.; Cristianawati, O.; Brinke, A. ten; Verstegen, N.J.M.; Zwinderman, K.A.H.; Ham, S.M. van; Rispens, T.; Welkers, M.R.; Jonges, M.; Eftimov, F.; Kuijpers, T.W. & T2B Immunity Against SARS-COV-2 Study Grp (2024), Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapy, Journal of Allergy and Clinical Immunology 154(3): 754-+.
- Meulen, S. van der; Monahan, R.C.; Gelderman, K.A.; Kooten, C. van; Teng, Y.K.O.; Huizinga, T.W.J.; Steup-Beekman, G.M. & Trouw, L.A. (2024), Circulating levels of endogenous complement inhibitors correlate inversely with complement consumption in systemic lupus erythematosus, European Journal of Immunology 54(11).
- Kronbichler, A.; Barnini, C.; Matyjek, A.; Gauckler, P.; Bruchfeld, A.; Caravaca-Fontan, F.; Floege, J.; Frangou, E.; Mirioglu, S.; Moran, S.M.; Stevens, K.; Teng, Y.K.O.; Steiger, S. & Immunonephrology Working Group European Renal Assoc (2024), Antibody-mediated podocytopathies, Nephrology Dialysis Transplantation 40(2).
- Wind, M.; Fierro, J.J.; Bloemenkamp, K.W.M.; Leeuw, K. de; Lely, A.T.; Limper, M.; Sueters, M.; Teng, Y.K.O.; Walter, I.J. & Kooiman, J. (2024), Pregnancy outcome predictors in systemic lupus erythematosus, The Lancet Rheumatology 6(10): e667-e683.
- Schaik, M. van; Bredewold, O.W.; Priester, M.; Michels, W.M.; Rabelink, T.J.; Rotmans, J. & Teng, Y.K.O. (2024), Long-term renal and cardiovascular risks of tacrolimus in patients with lupus nephritis, Nephrology Dialysis Transplantation.
- Frangou, E.; Anders, H.J.; Bajema, I.M.; Teng, Y.K.O.; Malvar, A.; Rovin, B.H. & Kronbichler, A. (2024), Immunosuppression Withdrawal in Patients with Lupus Nephritis, Journal of the American Society of Nephrology 35(7): 955-958.
- Wind, M.; Dekker, L.; Akker-van Marle, M.E. van den; Ballieux, B.E.P.B.; Cobbaert, C.M.; Rabelink, T.J.; Lith, J.M.M. van; Teng, Y.K.O. & Sueters, M. (2024), The addition of the sFlt-1/PlGF ratio to the protein/creatinine ratio in multiple pregnancy, Pregnancy Hypertension 36.
- Mirioglu, S.; Bruchfeld, A.; Caravaca-Fontan, F.; Fernandez-Juarez, G.M.; Floege, J.; Frangou, E.; Goumenos, D.; Griffith, M.; Moran, S.M.; Stevens, K.; Teng, Y.K.O.; Turkmen, K.; Kronbichler, A.; Steiger, S.; Immunonephrol Working Grp IWG & European Renal Association ERA (2024), Immunoengineering for autoimmune-kidney disease, Nephrology Dialysis Transplantation 39(12): 1934-1937.
- Dam, L. van; Younis, S.; Moon, J.S.; Zhang, M.R.; Parfasar, S.; Horomanski, A.; Sharpe, O.; Leeuwen, J. van; Lanz, T.; Kooten, C. van; Teng, O. & Robinson, W. (2024), Identification of Autoreactive Cytotoxic T Cells in ANCA-Associated Vasculitis, Arthritis & Rheumatology 76: 3781-3785.
- Aranow, C.; Allaart, C.F.; Amoura, Z.; Bruce, I.N.; Cagnoli, P.C.; Chatham, W.W.; Clark, K.L.; Furie, R.; Groark, J.; Urowitz, M.B.; Vollenhoven, R. van; Daniels, M.; Fox, N.L.; Gregan, Y.I.; Henderson, R.B.; Maurik, A. van; Ocran-Appiah, J.C.; Oldham, M.; Roth, D.A.; Shanahan, D.; Tak, P.P. & Teng, Y.O. (2024), Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study, Annals of the Rheumatic Diseases 83(11): 1502-1512.
- Arends, E.J.; Zlei, M.; Tipton, C.M.; Cotic, J.; Osmani, Z.; Bie, F.J. de; Kamerling, S.W.A.; Maurik, A. van; Dimelow, R.; Gregan, Y.I.; Fox, N.L.; Rabelink, T.J.; Roth, D.A.; Sanz, I.; Dongen, J.J.M. van; Kooten, C. van & Teng, Y.K.O. (2024), Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus, Rheumatology 63(9): 2387-2398.
- Schaik, M. van; Vries, A.P.J. de; Bemelman, F.J.; Rabelink, T.J.; Trouw, L.A.; Kooten, C. van & Teng, Y.K.O. (2024), Clinical Remission and Reduction of Circulating Nephritic Factors by Combining Rituximab With Belimumab in a Case of Complement Factor 3 Glomerulopathy, Kidney International Reports 9(6): 1919-1922.
- Saxena, A.; Ginzler, E.M.; Gibson, K.; Satirapoj, B.; Santillán, A.E.Z.; Levchenko, O.; Navarra, S.; Atsumi, T.; Yasuda, S.; Chavez-Perez, N.N.; Arriens, C.; Parikh, S.V.; Caster, D.J.; Birardi, V.; Randhawa, S.; Lisk, L.; Huizinga, R.B. & Teng, Y.K.O. (2024), Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial, Arthritis & Rheumatology 76(1): 59-67.
- Leeuwen, J.R. van; Penne, E.L.; Rabelink, T.; Knevel, R. & Teng, Y.K.O. (2024), Using an artificial intelligence tool incorporating natural language processing to identify patients with a diagnosis of ANCA-associated vasculitis in electronic health records, Computers in Biology and Medicine 168.
- Arriens, C.; Teng, Y.K.O.; Ginzler, E.M.; Parikh, S.V.; Askanase, A.D.; Saxena, A.; Gibson, K.; Caster, D.J.; Atsumi, T.; Lisk, L.; Randhawa, S.; Gluck, R.; Solomons, N. & Huizinga, R.B. (2023), Update on the efficacy and safety profile of voclosporin, Arthritis Care & Research.
- Dam, K.P.J. van; Volkers, A.G.; Wieske, L.; Stalman, E.W.; Kummer, L.Y.L.; Kempen, Z.L.E. van; Killestein, J.; Tas, S.W.; Boekel, L.; Wolbink, G.J.; Kooi, A.J. van der; Raaphorst, J.; Takkenberg, R.B.; D'Haens, G.R.A.M.I.; Spuls, P.W.; Bekkenk, M.H.; Musters, A.F.; Post, N.L.; Bosma, A.L.; Hilhorst, M.; Vegting, Y.J.; Bemelman, F.E.; Voskuyl, A.; Broens, B.; Sanchez, A.P.; Els, C.A.C.M. van; Wit, J. de; Rutgers, A.; Leeuw, K. de; Horvath, B.; Verschuuren, J.J.G.M.M.; Ruiter, A.M.; Ouwerkerk, L. van; Woude, D. van der; Allaart, R.C.F.; Teng, Y.K.O.; Paassen, P.H. van; Busch, M.H.; Jallah, P.B.P.; Brusse, E.; Doorn, P.A. van; Baars, A.E.; Hijnen, D.J.; Schreurs, C.R.G.; Pol, W.L. van der; Goedee, H.S.; Steenhuis, M.; Keijzer, S.; Keijser, J.B.D.; Cristianawati, O.; Brinke, A. ten; Verstegen, N.J.M.; Ham, S.M. van; Rispens, T.W.; Kuijpers, T.; Lowenberg, M.; Eftimov, F. & TB2 Immunity Sars-Cov-2 Study Grp (2023), Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases, BMC Infectious Diseases 23(1).
- Essen, M. van; Schlagwein, N.; Gijlswijk-Janssen, D. van; Teng, O. & Kooten, C. van (2023), Keeping properdin in check: Serum component(s) inhibit(s) the binding of properdin, Immunobiology 228(5): 83-84.
- Leeuwen, J.R.V.; Rabelink, T.J. & Teng, Y.K.O. (2023), Response to "Tailored Use of Avacopan in a Case With Refractory Antineutrophil Cytoplasmic Autoantibody-Associated Renal Vasculitis and Concominant Complement System Activation".
- Arends, E.J.; Meziyerh, S.; Moes, D.J.A.R.; Kamerling, S.W.A.; Kooy, S. van der; Ogando, N.S.; Snijder, E.J.; Hemert, M. van; Visser, L.G.; Feltkamp, M.C.W.; Claas, E.C.J.; Rabelink, T.J.; Kooten, C. van; Vries, A.P.J. de & Teng, Y.K.O. (2023), Voclosporin and the antiviral effect against SARS-CoV-2 in immunocompromised kidney patients, Kidney International Reports 8(12): 2654-2664.
- Koers, J.; Sciarrillo, R.; Derksen, N.I.L.; Vletter, E.M.; Fillie-Grijpma, Y.E.; Raveling-Eelsing, E.; Graca, N.A.G.; Leijser, T.; Pas, H.H.; Nijen-Vos, L.L. van; Braham, M.V.J.; Buisman, A.M.; Jong, J. de; Schriek, A.I.; Tio-Gillen, A.P.; Teng, Y.K.O.; Steenhuis, M.; Swaneveld, F.H.; Taeye, S.W. de; Gils, M.J. van; Verschuuren, J.J.G.M.; Rutgers, B.; Heeringa, P.; Horvath, B.; Jacobs, B.C.; Leeuw, K. de; Franssen, C.F.M.; Veyradier, A.; Coppo, P.; Gelderman, K.A.; Ham, D.H.S.M. van; Els, C.A.C.M. van; Woude, D. van der; Huizinga, R.; Huijbers, M.G.; Kuijpers, T.W.; Toes, R.E.M.; Bos, N.A.; Rispens, T. & T2B Consortium (2023), Differences in IgG autoantibody Fab glycosylation across autoimmune diseases, Journal of Allergy and Clinical Immunology 151(6): 1646-1654.
- Hellmich, B.; Sanchez-Alamo, B.; Schirmer, J.H.; Berti, A.; Blockmans, D.; Cid, M.C.; Holle, J.U.; Hollinger, N.; Karadag, O.; Kronbichler, A.; Little, M.A.; Luqmani, R.A.; Mahr, A.; Merkel, P.A.; Mohammad, A.J.; Monti, S.; Mukhtyar, C.B.; Musial, J.; Price-Kuehne, F.; Segelmark, M.; Teng, Y.K.O.; Terrier, B.; Tomasson, G.; Vaglio, A.; Vassilopoulos, D.; Verhoeven, P. & Jayne, D. (2023), EULAR recommendations for the management of ANCA-associated vasculitis, Annals of the Rheumatic Diseases 83.
- Fanouriakis, A.; Kostopoulou, M.; Andersen, J.; Aringer, M.; Arnaud, L.; Bae, S.C.; Boletis, J.; Bruce, I.N.; Cervera, R.; Doria, A.; Doerner, T.; Furie, R.A.; Gladman, D.D.; Houssiau, F.A.; Inês, L.S.; Jayne, D.; Kouloumas, M.; Kovács, L.; Mok, C.C.; Morand, E.F.; Moroni, G.; Mosca, M.; Mucke, J.; Mukhtyar, C.B.; Nagy, G.; Navarra, S.; Parodis, I.; Pego-Reigosa, J.M.; Petri, M.; Pons-Estel, B.A.; Schneider, M.; Smolen, J.S.; Svenungsson, E.; Tanaka, Y.; Tektonidou, M.G.; Teng, Y.O.; Tincani, A.; Vital, E.M.; Vollenhoven, R.F. van; Wincup, C.; Bertsias, G. & Boumpas, D.T. (2023), EULAR recommendations for the management of systemic lupus erythematosus, Annals of the Rheumatic Diseases 83.
- Leeuwen, J. van; Hafemann, S. & Teng, Y.K.O. (2023), IMPACT OF THE 2022 ACR/EULAR CLASSIFICATION CRITERIA ON CLINICAL DIAGNOSIS OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA) ASSOCIATED VASCULITIS, Annals of the Rheumatic Diseases 82: 919-920.
- Leeuwen, J.R. van; Hafemann, S.; Boog, P. van der; Woude, D. van der; Rabelink, T. & Teng, Y.K.O. (2023), The impact of reclassification by the 2022 ACR/EULAR classification criteria on risk factors for relapse in patients with ANCA-associated vasculitis, Clinical Kidney Journal 16(12): 2754-2756.
- Leeuwen, J. van; Penne, E. & Teng, Y.K.O. (2023), USING ARTIFICIAL INTELLIGENCE TO IDENTIFY ANTINEUTROPHIL CYTOPLASMATIC ANTIBODY (ANCA)ASSOCIATED VASCULITIS PATIENTS IN ELECTRONIC HEALTH RECORDS, Annals of the Rheumatic Diseases 82: 922-923.
- Rovin, B.H.; Furie, R.; Teng, Y.K.O.; Contreras, G.; Malvar, A.; Yu, X.Q.; Ji, B.; Green, Y.; Gonzalez-Rivera, T.; Bass, D.; Gilbride, J.; Tang, C.H. & Roth, D.A. (2022), A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis, Kidney International 101(2): 403-413.
- Saxena, A.; Teng, Y.K.O.; Collins, C.; England, N. & Leher, H. (2022), VOCLOSPORIN FOR LUPUS NEPHRITIS: RESULTS OF THE TWO-YEAR AURORA 2 CONTINUATION STUDY, Annals of the Rheumatic Diseases 81: 325-325.
- Teng, Y.K.O.; Saxena, A.; Palmen, M.; Birardi, V. & Lisk, L. (2022), VOCLOSPORIN FOR LUPUS NEPHRITIS: RESULTS OF THE TWO-YEAR AURORA 2 CONTINUATION STUDY, Nephrology Dialysis Transplantation 37: I819-I820.
- Teng, Y.K.O. & Rabelink, T.J.J. (2022), Will New Treatment Options for Lupus Nephritis Be Affordable?, Clinical Journal of the American Society of Nephrology 17(3): 340-341.
- Ahmed, W.U.R.; Bhatia, S.; McLean, K.A.; Khaw, R.; Baker, D.; Kamarajah, S.K.; Bell, S.; Nepogodiev, D.; Harrison, E.M.; Glasbey, J.C.; Borakati, A.; Burke, J.; Drake, T.M.; Bath, M.F.; Claireaux, H.A.; Gundogan, B.; Mohan, M.; Deekonda, P.; Kong, C.; Joyce, H.; McNamee, L.; Woin, E.; Khatri, C.; Fitzgerald, J.E.; Bhangu, A.; Arulkumaran, N.; Duthie, F.; Hughes, J.; Pinkney, T.D.; Prowle, J.; Richards, T.; Thomas, M.; Blanco-Colino, R.; Chapman, S.J.; Pata, F.; Pellino, G.; Sgro, A.; Soares, A.; Elst, T. van; Straten, S. van; Knowles, C.H.; Dynes, K.; Patel, M.; Patel, P.; Wigley, C.; Suresh, R.; Shaw, A.; Klimach, S.; Jull, P.; Evans, D.; Preece, R.; Ibrahim, I.; Manikavasagar, V.; Smith, R.; Brown, F.S.; Teo, R.; Sim, D.P.Y.; Logan, A.E.; Barai, I.; Amin, H.; Suresh, S.; Sethi, R.; Gul, W.; Bolton, W.; Corbridge, O.; Horne, L.; Attalla, M.; Morley, R.; Robinson, C.; Hoskins, T.; McAllister, R.; Lee, S.; Dennis, Y.; Nixon, G.; Heywood, E.; Wilson, H.; Ng, L.; Samaraweera, S.; Mills, A.; Doherty, C.; Belchos, J.; Phan, V.; Lim, M.; Miller, F.A.; Chouari, T.; Gardner, T.; Goergen, N.; Hayes, J.D.B.; MacLeod, C.S.; McCormack, R.; McKinley, A.; McKinstry, S.; Milligan, W.; Ooi, L.; Rafiq, N.M.; Sammut, T.; Sinclair, E.; Smith, M.; Wong, J.; Ablett, A.D.; Tie-Gill, T.; Ramsay, G.; Paola, L. de; McGuckin, S.; Alshakhs, A.; Ahmeidat, A.; Francis, A.A.; Baker, C.; Boulton, A.P.R.; Collins, J.; Copley, H.C.; Fearnhead, N.; Fox, H.; Mah, T.; McKenna, J.; Naruka, V.; Nigam, N.; Nourallah, B.; Perera, S.; Qureshi, A.; Saggar, S.; Sun, L.; Wang, X.; Yang, D.D.; Ali, Z.; Mullarkey, L.; Walshe, R.; Lewis, E.; Berry, B.; Moneim, J.; Mookerjee, S.; Al-hadithi, A.; Caroll, P.; Doyle, C.; Elangovan, S.; Falamarzi, A.; Perai, K.G.; Greenan, E.; Jain, D.; Lang-Orsini, M.; Lim, S.; Ridgway, P.; Laan, S. van der; Arthur, J.; Barclay, J.; Bradley, P.; Edwin, C.; Finch, E.; Hayashi, E.; Hopkins, M.; Kelly, D.; Kelly, M.; McCartan, N.; Ormrod, A.; Pakenham, A.; Christy, S.; Hayward, J.; Hitchen, C.; Kishore, A.; Martins, T.; Philomen, J.; Rao, R.; Rickards, C.; Burns, N.; Copeland, M.; Durand, C.; Dyal, A.; Ghaffar, A.; Gidwani, A.; Grant, M.; Gribbon, C.; Gruhn, A.; Leer, M.; Ojofeitimi, O.; Carroll, L.; Hylands, A.; Delaugere, L.P.; Reveendran, D.; Ahmad, K.; Beattie, G.; Beatty, M.; Campbell, G.; Donaldson, G.; Graham, S.; Holmes, D.; Kanabar, S.; Liu, H.; McCann, C.; Stewart, R.; Vara, S.; Coulter, C.; Ralston, C.; Laverty, L.; Gallagher, P.; Ajibola-Taylor, O.; Andah, E.J.E.; Ani, C.; Cabdi, N.M.O.; Ito, G.; Jones, M.; Komoriyama, A.; Titu, L.; Ahmed, A.; Yeo, Y.Q.; Elliott, D.; Bennett, J.; Mcnamara, M.; Sivarajah, S.; Dunmore, C.; Basra, M.; Gallogly, P.; Harinath, G.; Leong, S.H.; Pradhan, A.; Siddiqui, I.; Zaat, S.; Ali, A.; Galea, M.; Looi, W.L.; Ng, J.C.K.; Farhan-Alanie, M.M.H.; Aitken, G.; Nair, M.; Aly, M.H.; Buari, M.; Atkin, G.; Azizi, A.; Cargill, Z.; China, Z.; Elliot, J.; Jebakumar, R.; Lam, J.; Mudalige, G.; Onyerindu, C.; Renju, M.; Babu, V.S.; Ahmed, K.; Sheikh, Z.; Monks, M.; Lehmann, J.; Rotimi, O.; Hussain, M.; Joji, N.; Lovett, B.; Mownah, H.; Dwyer-Hemmings, L.; Busuttil, A.; Powell, J.; Hensher, C.; Vivian, F.; Ali, B.; Cresswell, B.; Dhillon, A.K.; Dupaguntla, Y.S.; Hungwe, C.; Lowe-Zinola, J.D.; Tsang, J.C.H.; Wcislo, K.; Bevan, K.; Cardus, C.; Duggal, A.; Hossain, S.; McHugh, M.; Scott, M.; Millar, Z.; Hirosue, S.; Ogunmwonyi, I.; Nakakande, D.; Chan, F.; Evans, R.; Gurung, E.; Haughey, B.; Jacob-Ramsdale, B.; Kerr, M.; Lee, J.; McCann, E.; Reid, N.; Kwek, I.; Gaze, H.; Nirmalanantha, A.; Amran, M.A. bin; Foulkes, A.; Jones, N.; Lau, I.S.F.; Hayat, F.; Hodgson, S.; Johnston, R.; Jones, W.; Khan, M.; Linn, T.; Long, S.; Seetharam, P.; Shaman, S.; Smart, B.; Pillai, S.; Khoury, G.; Powell, T.; Maleyko, I.; Sangheli, A.; Ransome, M.; Isse, M.; Aromolaran, O.; Bholah, H.; Anilkumar, A.; Davies, J.; Griffith, J.; Hughes, B.; Islam, Y.; Kidanu, D.; Mushaini, N.; Qamar, I. & Robi (2022), Validation of the OAKS prognostic model for acute kidney injury after gastrointestinal surgery, BJS Open 6(1).
- Ogando, N.S.; Metscher, E.; Moes, D.J.A.R.; Arends, E.J.; Tas, A.; Cross, J.; Snijder, E.J.; Teng, Y.K.O.; Vries, A.P.J. de & Hemert, M.J. van (2022), The cyclophilin-dependent calcineurin inhibitor voclosporin inhibits SARS-CoV-2 replication in cell culture, Transplant International 35.
- Furie, R.; Rovin, B.H.; Houssiau, F.; Contreras, G.; Teng, Y.K.O.; Curtis, P.; Green, Y.; Okily, M.; Madan, A. & Roth, D.A. (2022), Safety and efficacy of belimumab in patients with lupus nephritis, Clinical Journal of the American Society of Nephrology 17(11): 1620-1630.
- Wieske, L.; Kummer, L.Y.L.; Dam, K.P.J. van; Stalman, E.W.; Kooi, A.J. van der; Raaphorst, J.; Lowenberg, M.; Takkenberg, R.B.; Volkers, A.G.; D'Haens, G.R.A.M.; Tas, S.W.; Spuls, P.I.; Bekkenk, M.W.; Musters, A.H.; Post, N.F.; Bosma, A.L.; Hilhorst, M.L.; Vegting, Y.; Bemelman, F.J.; Killestein, J.; Kempen, Z.L.E. van; Voskuyl, A.E.; Broens, B.; Sanchez, A.P.; Wolbink, G.; Boekel, L.; Rutgers, A.; Leeuw, K. de; Horvath, B.; Verschuuren, J.J.G.M.; Ruiter, A.M.; Ouwerkerk, L. van; Woude, D. van der; Allaart, C.F.; Teng, Y.K.O.; Paassen, P. van; Busch, M.H.; Jallah, B.P.; Brusse, E.; Doorn, P.A. van; Baars, A.E.; Hijnen, D.; Schreurs, C.R.G.; Pol, W.L. van der; Goedee, H.S.; Steenhuis, M.; Rispens, T.; Brinke, A. ten; Verstegen, N.J.M.; Zwinderman, K.A.H.; Ham, S.M. van; Kuijpers, T.W.; Eftimov, F. & T2b Immunity SARS-CoV-2 Study Grp (2022), Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases, BMC Medicine 20(1).
- Bhoelan, S.; Howard, J.B.; Tichelaar, V.; Daele, P. van; Hak, L.; Voskuyl, A.; Limper, M.; Goekoop, R.; Teng, O.; Vosters, J.; Bijl, M.; Zirkzee, E.; Schilder, A.; Moens, H.B.; Leeuw, K. de & Meijer, K. (2022), Recurrence risk of venous thromboembolism associated with systemic lupus erythematosus, Research and Practice in Thrombosis and Haemostasis 6(8).
- Teng, Y.K.O.; Maurik, A. van; Clark, K.L.; Fox, N.L.; Gregan, Y.I.; Groark, J.; Henderson, R.; Ocran-Appiah, J.; Roth, D.; Shanahan, D.; Tak, P.P. & Aranow, C. (2022), PHARMACODYNAMIC EFFECT OF SEQUENTIAL BELIMUMAB (BEL) AND RITUXIMAB (RTX) THERAPY IN PATIENTS (PTS) WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): THE PHASE 3, RANDOMISED, PLACEBO-CONTROLLED BLISS-BELIEVE STUDY, Annals of the Rheumatic Diseases 81: 186-187.
- Klomp, S.; Meziyerh, S.; Vissers, M.; Moes, D.; Arends, E.; Teng, O.; Vries, D. & Swen, J. (2022), INCREASED TACROLIMUS EXPOSURE IN KIDNEY TRANSPLANT RECIPIENTS WITH COVID-19: INFLAMMATION-DRIVEN INHIBITION OF METABOLISM AS A POTENTIAL MECHANISM., Clinical Pharmacology & Therapeutics 111: S27-S27.
- Klomp, S.D.; Meziyerh, S.; Vissers, M.F.J.M.; Moes, D.J.A.R.; Arends, E.J.; Teng, Y.K.O.; Swen, J.J. & Vries, A.P.J. de (2022), Increased tacrolimus exposure in kidney transplant recipients with COVID-19 , Transplant International 35.
- Dirikgil, E.; Tas, S.W.; Verburgh, C.A.; Soonawala, D.; Hak, A.E.; Remmelts, H.H.F.; IJpelaar, D.; Laverman, G.D.; Rutgers, A.; Laar, J.M. van; Moens, H.J.B.; Verhoeven, P.M.J.; Rabelink, T.J.; Bos, W.J.W.; Teng, Y.K.O. & Autoimmune Research Collaboration Hub (ARCH) study group (2022), Identifying relevant determinants of in-hospital time to diagnosis for ANCA-associated vasculitis patients, Rheumatology Advances in Practice 6(2).
- Wieske, L.; Dam, K.P.J. van; Steenhuis, M.; Stalman, E.W.; Kummer, L.Y.L.; Kempen, Z.L.E. van; Killestein, J.; Volkers, A.G.; Tas, S.W.; Boekel, L.; Wolbink, G.J.; Kooi, A.J. van der; Raaphorst, J.; Lowenberg, M.; Takkenberg, R.B.; D'Haens, G.R.A.M.; Spuls, P.I.; Bekkenk, M.W.; Musters, A.H.; Post, N.F.; Bosma, A.L.; Hilhorst, M.L.; Vegting, Y.; Bemelman, F.J.; Voskuyl, A.E.; Broens, B.; Sanchez, A.P.; Els, C.A.C.M. van; Wit, J. de; Rutgers, A.; Leeuw, K. de; Horvath, B.; Verschuuren, J.J.G.M.; Ruiter, A.M.; Ouwerkerk, L. van; Woude, D. van der; Allaart, R.C.F.; Teng, Y.K.O.; Paassen, P. van; Busch, M.H.; Jallah, P.B.P.; Brusse, E.; Doorn, P.A. van; Baars, A.E.; Hijnen, D.J.; Schreurs, C.R.G.; Pol, W.L. van der; Goedee, H.S.; Keijzer, S.; Keijser, J.B.D.; Boogaard, A.; Cristianawati, O.; Brinke, A. ten; Verstegen, N.J.M.; Zwinderman, K.A.H.; Ham, S.M. van; Kuijpers, T.W.; Rispens, T.; Eftimov, F. & T2B Immunity SARS-CoV-2 Study Grp (2022), Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants, The Lancet Rheumatology 4(5): E338-E350.
- Dirikgil, E.; Leeuwen, J.R. van; Bredewold, O.W.; Ray, A.; Jonker, J.T.; Soonawala, D.; Remmelts, H.H.F.; Dam, B. van; Bos, W.J.; Kooten, C. van; Rotmans, J.; Rabelink, T. & Teng, Y.K.O. (2022), ExploriNg DUrable Remission with Rituximab in ANCA-associatEd vasculitis (ENDURRANCE trial), BMJ Open 12(9).
- Wortel, C.; Wetering, R. van de; Dooren, H. van; Stork, E.M.; Bakker, A.M.; Brehler, A.S.; Kissel, T.; Reijm, S.; Stoeken-Rijsbergen, G.; Schie, K. van; Rutgers, A.; Trouw, L.A.; Huizinga, T.; Teng, Y.K.O.; Kooten, C. van; Heeringa, P.; Toes, R. & Scherer, H.U. (2022), EXPANSION OF MYELOPEROXIDASE (MPO)-SPECIFIC IGM B CELLS IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)-ASSOCIATED VASCULITIS, Annals of the Rheumatic Diseases 81: 61-61.
- Schaik, M. van; Arends, E.J.; Soonawala, D.; Ommen, E. van; Leeuw, K. de; Limper, M.; Paassen, P. van; Huizinga, T.W.J.; Toes, R.E.M.; Kooten, C. van; Rotmans, J.I.; Rabelink, T.J. & Teng, Y.K.O. (2022), Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: , Trials 23(1).
- Dirikgil, E.; Brons, K.; Duindam, M.; Groeneveld, G.H.; Geelhoed, J.J.M.; Heringhaus, C.; Boog, P.J.M. van der; Rabelink, T.J.; Bos, W.J.W.; Chavannes, N.H.; Atsma, D.E. & Teng, Y.K.O. (2022), COVID-box experiences of patients and health care professionals (COVID-box project), JMIR Formative Research 6(7).
- Leeuwen, J.R. van; Bredewold, O.W.; Dam, L.S. van; Werkman, S.L.; Jonker, J.T.; Geelhoed, M.; Langeveld, A.P.M.; Remmelts, H.H.F.; Broecke, M.M. van den; Ray, A.; Rabelink, T.J. & Teng, Y.K.O. (2022), Compassionate Use of Avacopan in Difficult-to-Treat Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
- Wind, M.; Akker-van Marle, M.E. van den; Ballieux, B.E.P.B.; Cobbaert, C.M.; Rabelink, T.J.; Lith, J.M.M. van; Teng, Y.K.O. & Sueters, M. (2022), Clinical value and cost analysis of the sFlt-1/PlGF ratio in addition to the spot urine protein/creatinine ratio in women with suspected pre-eclampsia , BMC Pregnancy and Childbirth 22(1).
- Boekel, L.; Stalman, E.W.; Wieske, L.; Hooijberg, F.; Dam, K.P.J. van; Besten, Y.R.; Kummer, L.Y.L.; Steenhuis, M.; Kempen, Z.L.E. van; Killestein, J.; Volkers, A.G.; Tas, S.W.; Kooi, A.J. van der; Raaphorst, J.; Lowenberg, M.; Takkenberg, R.B.; D'Haens, G.R.A.M.; Spuls, P.I.; Bekkenk, M.W.; Musters, A.H.; Post, N.F.; Bosma, A.L.; Hilhorst, M.L.; Vegting, Y.; Bemelman, F.J.; Voskuyl, A.E.; Broens, B.; Sanchez, A.P.; Els, C.A.C.M. van; Wit, J. de; Rutgers, A.; Leeuw, K. de; Horvath, B.; Verschuuren, J.J.G.M.; Ruiter, A.M.; Ouwerkerk, L. van; Woude, D. van der; Allaart, C.F.; Teng, Y.K.O.; Paassen, P. van; Busch, M.H.; Jallah, P.B.P.; Brusse, E.; Doorn, P.A. van; Baars, A.E.; Hijnen, D.J.; Schreurs, C.R.G.; Pol, W.L. van der; Goedee, H.S.; Vogelzang, E.H.; Leeuw, M.; Atiqi, S.; Vollenhoven, R. van; Gerritsen, M.; Horst-Bruinsma, I.E. van der; Lems, W.F.; Nurmohamed, M.T.; Boers, M.; Keijzer, S.; Keijser, J.; Sandt, C. van de; Boogaard, A.; Cristianawati, O.; Brinke, A. ten; Verstegen, N.J.M.; Zwinderman, K.A.H.; Ham, S.M. van; Rispens, T.; Kuijpers, T.W.; Wolbink, G. & Eftimov, F. (2022), Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants , The Lancet Rheumatology 4(6): E417-E429.
- Stalman, E.W.; Wieske, L.; Dam, K.P.J. van; Kummer, L.Y.; Kempen, Z.L.E. van; Killestein, J.; Volkers, A.G.; Tas, S.W.; Boekel, L.; Wolbink, G.J.; Kooi, A.J. van der; Raaphorst, J.; Lowenberg, M.; Takkenberg, R.B.; D'Haens, G.R.A.M.; Spuls, P.I.; Bekkenk, M.W.; Musters, A.H.; Post, N.F.; Bosma, A.L.; Hilhorst, M.L.; Vegting, Y.; Bemelman, F.J.; Voskuyl, A.E.; Broens, B.; Sanchez, A.P.; Els, C.A.C.M. van; Wit, J. de; Rutgers, A.; Leeuw, K. de; Horvath, B.; Verschuuren, J.J.G.M.; Ruiter, A.M.; Ouwerkerk, L. van; Woude, D. van der; Allaart, C.F.; Teng, O.Y.K.; Paassen, P. van; Busch, M.H.; Jallah, P.B.P.; Brusse, E.; Doorn, P.A. van; Baars, A.E.; Hijnen, D.J.; Schreurs, C.R.G.; Pol, W.L. van der; Goedee, H.S.; Steenhuis, M.; Keijzer, S.; Keijser, J.B.D.; Boogaard, A.; Cristianawati, O.; Brinke, A. ten; Verstegen, N.J.M.; Zwinderman, K.A.H.; Rispens, T.; Ham, S.M. van; Kuijpers, T.W.; Eftimov, F. & T2B Immunity Against SARS Co (2022), Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases, Annals of the Rheumatic Diseases 81(12).
- Arends, E.J.; Zlei, M.; Tipton, C.M.; Cotic, J.; Osmani, Z.; Bie, F. de; Kamerling, S.; Maurik, A. van; Dimelow, R.; Gregan, Y.I.; Fox, N.L.; Rabelink, T.; Roth, D.; Sanz, I.; Dongen, J.J.M. van; Kooten, C. van & Teng, Y.K.O. (2022), BELIMUMAB DISRUPTS MEMORY B-CELL TRAFFICKING IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS, Annals of the Rheumatic Diseases 81: 324-325.
- Arends, E.J.; Zlei, M.; Tipton, C.M.; Cotic, J.; Osmani, Z.; Bie, F.J. de; Kamerling, S.W.A.; Maurik, A. van; Dimelow, R.; Gregan, Y.I.; Fox, N.L.; Rabelink, T.J.; Roth, D.A.; Sanz, I.; Dongen, J.J.M. van; Kooten, C. van & Teng, O. (2022), Belimumab Disrupts Memory B-Cell Trafficking in Patients with Systemic Lupus Erythematosus, Arthritis & Rheumatology 74: 3292-3293.
- Arends, E.J.; Zlei, M.; Tipton, C.M.; Osmani, Z.; Bie, F. de; Kamerling, S.W.A.; Rabelink, T.; Sanz, I.; Dongen, J.J.M. van; Kooten, C. van & Teng, Y.K.O. (2022), BELIMUMAB DISRUPTS MEMORY B CELL TRAFFICKING IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS, Nephrology Dialysis Transplantation 37: I170-I170.
- Gool, I.C. van; Kers, J.; Bakker, J.A.; Rotmans, J.I.; Teng, Y.K.O. & Bauer, M.P. (2022), Antineutrophil cytoplasmic antibodies in infective endocarditis: a case report and systematic review of the literature, Clinical Rheumatology 41(10): 2949-2960.
- Alehashemi, S.; Jesus, A.A. de; Papendorf, J.J.; Bhuyan, F.; Uss, K.; Metpally, A.; Lin, B.; Park, S.; Moura, T.C.L.; Dias, R.R.; Dorna, M.B.; Kozu, K.; Sallum, A.; Campos, L.M.A.; Santen, G.; Kers, J.; Teng, O.; Palmblad, K.; Huizinga, T.; Ebstein, F.; Kruger, E. & Goldbach-Mansky, R. (2022), A De Novo Dominant-negative PSMB8 mutation is Linked to a More Severe CANDLE-like Phenotype, Arthritis and Rheumatology 74: 3826-3828.
- Wind, M.; Gaasbeek, A.G.A.; Oosten, L.E.M.; Rabelink, T.J.; Lith, J.M.M. van; Sueters, M. & Teng, Y.K.O. (2021), Therapeutic plasma exchange in pregnancy: a literature review, European Journal of Obstetrics and Gynecology and Reproductive Biology 260.
- Ouwerkerk, L. van; Meulen, A. van der; Ninaber, M.; Teng, Y.K.O.; Huizinga, T. & Allaart, C. (2021), A prospective study into Covid-19 like symptoms in patients with and without immune mediated inflammatory diseases or immunomodulating drugs, Annals of the Rheumatic Diseases 80: 1365-1366.
- Arends, E.J.; Zlei, M.; Tipton, C.M.; Osmani, Z.; Kamerling, S.; Rabelink, T.; Sanz, I.; Dongen, J.J.M. van; Kooten, C. van & Teng, Y.K.O. (2021), BELIMUMAB ADD-ON THERAPY MOBILISES MEMORY B CELLS INTO THE CIRCULATION OF PATIENTS WITH SLE, Annals of the Rheumatic Diseases 80: 585-585.
- Arends, E.J.; Zlei, M.; Tipton, C.M.; Osmani, Z.; Kamerling, S.W.A.; Rabelink, T.; Sanz, I.; Dongen, J.J.M. van; Kooten, C. van & Teng, Y.K.O. (2021), BELIMUMAB ADD-ON THERAPY MOBILIZES MEMORY B CELLS INTO CIRCULATION OF SLE PATIENTS, Nephrology Dialysis Transplantation 36.
- Dirikgil, E.; Jonker, J.T.; Tas, S.W.; Verburgh, C.A.; Soonawala, D.; Hak, A.E.; Remmelts, H.H.F.; IJpelaar, D.; Laverman, G.D.; Rutgers, A.; Laar, J.M. van; Moen, H.J.B.; Verhoeven, P.M.J.; Rabelink, T.J.; Bos, W.J.W.; Teng, Y.K.O. & Arthritis Res Collaboration Hub AR (2021), Clinical Practice Audit on the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in the Netherlands, Kidney International Reports 6(10): 2671-2678.
- Teng, Y.K.O.; Dam, L. van; Oskam, J.; Kamerling, S.W.A.; Arends, E.J.; Bredewold, E.; Dongen, J.J.M. van; Rabelink, T.J. & Kooten, C. van (2021), HIGHLY SENSITIVE FLOW CYTOMETRIC DETECTION OF RESIDUAL B-CELLS AFTER RITUXIMAB IN ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS PATIENTS, Nephrology Dialysis Transplantation 36.
- Kraaij, T.; Arends, E.J.; Dam, L.S. van; Kamerling, S.W.A.; Daele, P.L.A. van; Bredewold, O.W.; Ray, A.; Bakker, J.A.; Scherer, H.U.; Huizinga, T.J.W.; Rabelink, T.J.; Kooten, C. van & Teng, Y.K.O. (2021), Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus, Nephrology Dialysis Transplantation 36(8): 1474-1483.
- Dam, L.S. van; Dirikgil, E.; Bredewold, E.W.; Ray, A.; Bakker, J.A.; Kooten, C. van; Rabelink, T.J. & Teng, Y.K.O. (2021), PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab, Nephrology Dialysis Transplantation 36(8): 1408-1417.
- Ouwerkerk, L. van; Meulen-de Jong, A.E. van de; Ninaber, M.K.; Teng, Y.K.O.; Huizinga, T.W. & Allaart, C.F. (2021), Prospective study into COVID-19-like symptoms in patients with and without immune-mediated inflammatory diseases or immunomodulating drugs.
- Rovin, B.; Furie, R.; Houssiau, F.A.; Contreras, G.; Teng, Y.K.O.; Curtis, P.; Madan, A.; Jones-Leone, A.; Gonzalez-Rivera, T.; Okily, M. & Roth, D. (2021), SAFETY AND EFFICACY OF INTRAVENOUS BELIMUMAB IN PATIENTS WITH LUPUS NEPHRITIS: A 6-MONTH OPEN-LABEL EXTENSION, Nephrology Dialysis Transplantation 36.
- Dirikgil, E.; Roos, R.; Groeneveld, G.H.; Heringhaus, C.; Silven, A.V.; Petrus, A.H.J.; Villalobos-Quesada, M.; Tsonaka, R.; Boog, P.J.M.V.; Rabelink, T.J.; Bos, W.J.W.; Chavannes, N.H.; Atsma, D.E. & Teng, Y.K.O. (2021), Home monitoring reduced short stay admissions in suspected COVID-19 patients: COVID-box project.
- Rovin, B.H.; Teng, Y.K.O.; Ginzler, E.M.; Arriens, C.; Caster, D.J.; Romero-Diaz, J.; Gibson, K.; Kaplan, J.; Lisk, L.; Navarra, S.; Parikh, S.V.; Randhawa, S.; Solomons, N. & Huizinga, R.B. (2021), Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial, The Lancet 397(10289): 2070-2080.
- Groot, N.; Kardolus, A.; Bijl, M.; Dolhain, R.J.E.M.; Teng, Y.K.O.; Zirkzee, E.; Leeuw, K. de; Fritsch-Stork, R.; Burdorf, A.; Bultink, I.E. & Kamphuis, S. (2021), Effects of childhood-onset systemic lupus erythematosus on academic achievements and employment in adult life, The Journal of Rheumatology 48(6): 915-923.
- Teng, Y.K.O.; Pusey, C.D.; Vaglio, A.; Mok, C.C. & Kooten, C. van (2021), Editorial: immune monitoring responses in renal autoimmune diseases, Frontiers in Immunology 12.
- Stocker, J.K.; Vonk, M.C.; Hoogen, F.H.J. van den; Nijhuis-van der Sanden, M.W.G.; Spierings, J.; Staal, J.B.; Satink, T.; Ende, C.H.M. van den & ARCH Study Grp (2021), Opening the black box of non-pharmacological care in systemic sclerosis, Rheumatology International 41(7): 1299--1310.
- Wind, M.; Hendriks, M.; Brussel, B.T.J. van; Eikenboom, J.; Allaart, C.F.; Lamb, H.J.; Siebelink, H.M.J.; Ninaber, M.K.; Geloven, N. van; Lith, J.M.M. van; Huizinga, T.W.J.; Rabelink, T.J.; Sueters, M. & Teng, Y.K.O. (2021), Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome, Lupus Science & Medicine 8(1).
- Wind, M.; Gaasbeek, A.G.A.; Oosten, L.E.M.; Rabelink, T.J.; Lith, J.M.M. van; Sueters, M. & Teng, Y.K.O. (2021), Therapeutic plasma exchange in pregnancy: a literature review, European Journal of Obstetrics and Gynecology and Reproductive Biology 260: 29-36.
- Fanouriakis, A.; Kostopoulou, M.; Cheema, K.; Anders, H.J.; Aringer, M.; Bajema, I.; Boletis, J.; Frangou, E.; Houssiau, F.A.; Hollis, J.; Karras, A.; Marchiori, F.; Marks, S.D.; Moroni, G.; Mosca, M.; Parodis, I.; Praga, M.; Schneider, M.; Smolen, J.S.; Tesar, V.; Trachana, M.; Vollenhoven, R.F. van; Voskuyl, A.E.; Teng, Y.K.O.; Leew, B. van; Bertsias, G.; Jayne, D. & Boumpas, D.T. (2020), 2019 update of the joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis, Annals of the Rheumatic Diseases 79(6): 713-723.
- Kraaij, T.; Arends, E.J.; Dam, L.S. van; Kamerling, S.W.A.; Daele, P.L.A. van; Bredewold, O.W.; Ray, A.; Bakker, J.A.; Scherer, H.U.; Huizinga, T.J.W.; Rabelink, T.J.; Kooten, C. van & Teng, Y.K.O. (2020), Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results, Nephrology Dialysis Transplantation 36(8).
- Furie, R.; Rovin, B.H.; Houssiau, F.; Malvar, A.; Teng, Y.K.O.; Contreras, G.; Amoura, Z.; Yu, X.Q.; Mok, C.C.; Santiago, M.B.; Saxena, A.; Green, Y.; Ji, B.; Kleoudis, C.; Burriss, S.W.; Barnett, C. & Roth, D.A. (2020), Two-year, randomized, controlled trial of belimumab in lupus nephritis, New England Journal of Medicine 383(12): 1117-1128.
- Silven, A.V.; Petrus, A.H.J.; Villalobos-Quesada, M.; Dirikgil, E.; Oerlemans, C.R.; Landstra, C.P.; Boosman, H.; Os, H.J.A. van; Blanker, M.H.; Treskes, R.W.; Bonten, T.N.; Chavannes, N.H.; Atsma, D.E. & Teng, Y.K.O. (2020), Telemonitoring for patients with COVID-19, Journal of Medical Internet Research 22(9).
- Dam, L.S. van; Oskam, J.M.; Kamerling, S.W.A.; Arends, E.J.; Bredewold, O.W.; Berkowska, M.A.; Dongen, J.J.M. van; Rabelink, T.J.; Kooten, C. van & Teng, Y.K.O. (2020), Highly sensitive flow cytometric detection of residual B-cells after rituximab in anti-neutrophil cytoplasmic antibodies-associated vasculitis patients, Frontiers in Immunology 11.
- Dam, L.S. van; Dirikgil, E.; Bredewold, E.W.; Ray, A.; Bakker, J.A.; Kooten, C. van; Rabelink, T.J. & Teng, Y.K.O. (2020), Proteinase-3-anti-neutrophil cytoplasmic antibodies (PR3-ANCAs) predict relapses in ANCA-associated vasculitis patients after rituximab, Nephrology Dialysis Transplantation 36(8).
- Rovin, B.; Houssiau, F.A.; Furie, R.; Malvar, A.; Teng, Y.K.O.; Mok, C.C.; Contreras, G.; Yu, X.Q.; Dolff, S.; Ji, B.; Roth, D.; Kleoudis, C.; Bass, D.; Madan, A.; Wright, A.; Barnett, C. & Green, Y.L. (2020), EFFICACY AND SAFETY OF BELIMUMAB IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS: A PHASE 3, RANDOMISED, PLACEBO-CONTROLLED TRIAL, Nephrology Dialysis Transplantation 35: 2181-2182.
- Furie, R.; Rovin, B.; Houssiau, F.; Contreras, G.; Malvar, A.; Saxena, A.; Yu, X.Q.; Teng, K.O.; Paassen, P. van; Ginzler, E.M.; Kamen, D.; Oldham, M.; Bass, D.; Maurik, A. van; Welch, M.B.; Green, Y.; Ji, B.; Kleoudis, C. & Roth, D. (2020), Effects of Belimumab on Renal Outcomes, Overall SLE Control and Biomarkers: Findings from a Phase 3, Randomized, Placebo-controlled 104-week Study in Patients with Active Lupus Nephritis, Arthritis and Rheumatology 72.
- Dirikgil, E.; Rutgers, A.; Tas, S.; Verburgh, C.A.; Soonawala, D.; Hak, A.E.; Remmelts, H.H.F.; Ijpelaar, D.; Laverman, G.D.; Laar, J.M. van; Moens, H.J.B.; Verhoeven, P.; Bos, W.J.W. & Teng, Y.K.O. (2020), Clinical practice variation between academic and non-academic centers in the management of ANCA-associated vasculitis in the Netherlands, Annals of the Rheumatic Diseases 79: 376-377.
- Furie, R.; Rovin, B.H.; Houssiau, F.; Amoura, Z.; Santiago, M.; Contreras, G.; Malvar, A.; Mok, C.C.; Saxena, A.; Yu, X.; Teng, Y.K.O.; Barnett, C.; Burriss, S.; Green, Y.; Ji, B.; Kleoudis, C. & Roth, D. (2020), Bliss-LN: a randomised, double-blind, placebo-controlled phase 3 trial of intravenous belimumab in patients with active lupus nephritis , Annals of the Rheumatic Diseases 79: 103-103.
- Dam, L.S. van; Osmani, Z.; Kamerling, S.W.A.; Kraaij, T.; Bakker, J.A.; Scherer, H.U.; Rabelink, T.J.; Voll, R.E.; Alexander, T.; Isenberg, D.A.; Kooten, C. van & Teng, Y.K.O. (2020), A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE, Rheumatology 59(10): 2734-2745.
- Dirikgil, E.; Tas, S.W.; Rutgers, A.; Verhoeven, P.M.J.; Laar, J.M. van; Hagen, E.C.; Tekstra, J.; Hak, A.E.L.; Paassen, P. van; Kok, M.R.; Goldschmeding, R.; Dam, B. van; Douma, C.E.; Remmelts, H.H.F.; Sanders, J.F.; Jonker, J.T.; Rabelink, T.J.; Damoiseaux, J.G.M.C.; Moens, H.J.B.; Bos, W.J.W.; Teng, Y.K.O. & Arthrit Res Collaboration Hub Cons (2020), A Dutch consensus statement on the diagnosis and treatment of ANC A-associated vasculitis, Netherlands Journal of Medicine 78(2): 71-82.
- Fanouriakis, A.; Kostopoulou, M.; Cheema, K.; Anders, H.J.; Aringer, M.; Bajema, I.; Boletis, J.N.; Frangou, E.; Houssiau, F.; Hollis, J.; Karras, A.; Marchiori, F.; Marks, S.; Moroni, G.; Mosca, M.; Parodis, I.; Praga, M.; Schneider, M.; Smolen, J.S.; Tesar, V.; Trachana, M.; Vollenhoven, R.V.; Voskuyl, A.; Teng, Y.K.O.; Leeuw, B. van; Bertsias, G.; Jayne, D. & Boumpas, D. (2020), 2019 update of the joint European league against rheumatism and European renal association-European dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis, Annals of the Rheumatic Diseases 79: 102-103.
- Teng, Y.K.O.; Bruce, I.N.; Diamond, B.; Furie, R.A.; Vollenhoven, R.F. van; Gordon, D.; Groark, J.; Henderson, R.B.; Oldham, M. & Tak, P.P. (2019), Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE), BMJ Open 9(3): e025687.
- Kraaij, T.; Nilsson, S.C.; Kooten, C. van; Okroj, M.; Blom, A.M. & Teng, Y.K.O. (2019), Measuring plasma C4D to monitor immune complexes in lupus nephritis, Lupus Science & Medicine 6(1).
- Groot, N.; Shaikhani, D.; Teng, Y.K.O.; Leeuw, K. de; Bijl, M.; Dolhain, R.J.E.M.; Zirkzee, E.; Fritsch-Stork, R.; Bultink, I.E.M. & Kamphuis, S. (2019), Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus, Arthritis and Rheumatology 71(2): 290-301.
- Teng, Y.K.O.; Bruce, I.N.; Diamond, B.; Furie, R.A.; Vollenhoven, R.F. van; Gordon, D.; Groark, J.; Henderson, R.B.; Oldham, M. & Tak, P.P. (2019), Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol, BMJ Open 9(3).
- Dirikgil, E.; Verhoeven, P.; Tas, S.; Rutgers, A.; Moens, H.B.; Laar, J. van; Bos, W.J. & Teng, O. (2019), A Dutch Consensus Statement on the Diagnosis and Treatment of ANCA Associated Vasculitis, Arthritis and Rheumatology 71.
- Dam, L. van; Dirikgil, E.; Bredewold, E.; Ray, A.; Rabelink, T.; Kooten, C. van & Teng, O. (2019), ANCA Response upon Rituximab or Cyclophosphamide in ANCA-associated Vasculitis Patients, Arthritis and Rheumatology 71.
- Limper, M.; Leeuw, K. de; Lely, A.T.; Westerink, J.; Teng, Y.K.O.; Eikenboom, J.; Otter, S.; Jansen, A.J.G.; Ree, M. van der; Spierings, J.; Kruyt, N.D.; Molen, R. van der; Middeldorp, S.; Leebeek, F.W.G.; Bijl, M. & Urbanus, R.T. (2019), Diagnosing and treating antiphospholipid synarome: a consensus paper, Netherlands Journal of Medicine 77(3): 98-108.
- Dam, L.S. van; Kraaij, T.; Kamerling, S.W.A.; Bakker, J.A.; Scherer, U.H.; Rabelink, T.J.; Kooten, C. van & Teng, Y.K.O. (2019), Intrinsically Distinct Role of Neutrophil Extracellular Trap Formation in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Compared to Systemic Lupus Erythematosus, Arthritis and Rheumatology.
- Kraaij Tineke, Arends E. J., van Dam Laura, Kamerling Sylvia, van Daele Paul L. A., Bredewold Obbo Winne, Ray Argho, Bakker Jaap, Bajema Ingeborg, Scherer Hans Ulrich, Huizinga Thomas, Rabelink Ton, van Kooten Cees & Teng Y. K. Onno (2019), LONG-TERM EFFECTS OF SYNERGETIC B CELL IMMUNOMODULATION WITH RITUXIMAB AND BELIMUMAB COMBINATION TREATMENT IN SEVERE, REFRACTORY SLE: TWO YEAR RESULTS, Annals of the Rheumatic Diseases 78: 91-92.
- Dam, L. van; Oskam, J.; Kamerling, S.; Arends, E.; Bredewold, E.; Berkowska, M.; Dongen, J. van; Rabelink, T.; Kooten, C. van & Teng, O. (2019), Minimal Residual Autoimmunity After Rituximab in ANCA-associated Vasculitis Patients, Arthritis and Rheumatology 71.
- Arends, E.J.; Dam, L.S. van; Kraaij, T.; Kamerling, S.W.A.; Rabelink, T.J.; Kooten, C. van & Teng, Y.K.O. (2019), A high-throughput assay to assess and quantify neutrophil extracellular trap formation, Journal of Visualized Experiments 143.
- Arends, E.J.; Dam, L.S. van; Kraaij, T.; Kamerling, S.W.A.; Rabelink, T.J.; Kooten, C. van & Teng, Y.K.O. (2019), A High-throughput Assay to Assess and Quantify Neutrophil Extracellular Trap Formation, Journal of Visualized Experiments.
- Koopman, J.J.E.; Teng, Y.K.O.; Boon, C.J.F.; Heuvel, L.P. van den; Rabelink, T.J.; Kooten, C. van & Vries, A.P.J. de (2019), Diagnosis and treatment of C3 glomerulopathy in a center of expertise, Netherlands Journal of Medicine 77(1): 10-18.
- Dam, L.S. van; Rabelink, T.J.; Kooten, C. van & Teng, Y.K.O. (2019), Clinical Implications of Excessive Neutrophil Extracellular Trap Formation in Renal Autoimmune Diseases, Kidney International Reports 4(2): 196-211.
- Dam, L. van; Kraaij, T.; Kamerling, S.W.A.; Scherer, H.U.; Rabelink, T.; Kooten, C. van & Teng, Y.K.O. (2018), Excessive Formation of Neutrophil Extracellular Traps: Different Role in the Pathogenesis of ANCA-Associated Vasculitis and Systemic Lupus Erythematosus, Arthritis and Rheumatology 70.
- Rijnink, E.C.; Teng, Y.K.O.; Kraaij, T.; Dekkers, O.M.; Bruijn, J.A. & Bajema, I.M. (2018), Validation of the Systemic Lupus International Collaborating Clinics classification criteria in a cohort of patients with full house glomerular deposits, Kidney International 93(1): 214-220.
- Kraaij, T.; Kamerling, S.W.A.; Rooij, E.N.M. de; Daele, P.L.A. van; Bredewold, O.W.; Bakker, J.A.; Bajema, I.M.; Scherer, H.U.; Toes, R.E.M.; Huizinga, T.J.W.; Rabelink, T.J.; Kooten, C. van & Teng, Y.K.O. (2018), The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus, Journal of Autoimmunity 91: 45-54.
- Teng, Y.K.O.; Bredewold, E.O.W.; Rabelink, T.J.; Huizinga, T.W.J.; Eikenboom, H.C.J.; Limper, M.; Fritsch-Stork, R.D.E.; Bloemenkamp, K.W.M. & Sueters, M. (2018), An evidence-based approach to pre-pregnancy counselling for patients with systemic lupus erythematosus, Rheumatology 57(10): 1707-1720.
- Kester, M.S. van; Langeveld, T.J.C.; Bouwsma, H.; Rees, J.B. van; Holman, E.R.; Teng, Y.K.O. & Zuuren, E.J. van (2018), A breathtaking DRESS due to amoxicillin-clavulanate presenting as polymorphic eruption of the pregnancy, Journal of the European Academy of Dermatology and Venereology 32(12): E436-E437.
- Kraaij, T.; Kamerling, S.W.A.; Dam, L.S. van; Bakker, J.A.; Bajema, I.M.; Page, T.; Brunini, F.; Pusey, C.D.; Toes, R.E.M.; Scherer, H.U.; Rabelink, T.J.; Kooten, C. van & Teng, Y.K.O. (2018), Excessive neutrophil extracellular trap formation in ANCA-associated vasculitis is independent of ANCA, Kidney International 94(1): 139-149.
- van Dam Laura, Kraaij Tineke, Kamerling Sylvia, Scherer Hans, Rabelink Ton, van Kooten Cees & Teng Y. (2018), EXCESSIVE FORMATION OF NEUTROPHIL EXTRACELLULAR TRAPS HAVE A DIFFERENT ROLE IN THE PATHOGENESIS OF ANCA-ASSOCIATED VASCULITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS, Nephrology Dialysis Transplantation 33: 329-U112.
- Kraaij, T.; Kamerling, S.W.A.; Rooij, E.N.M. de; Daele, P.L. van; Bredewold, O.W.; Bakker, J.A.; Bajema, I.; Scherer, H.U.; Toes, R.E.M.; Huizinga, T.W.J.; Rabelink, T.; Kooten, C. van & Teng, Y.K.O. (2017), Synergetic B-Cell Immunomodulation with Rituximab and Belimumab Combination Treatment in Severe, Refractory SLE, Arthritis and Rheumatology 69.
- Rijnink, E.C.; Teng, Y.K.O.; Wilhelmus, S.; Almekinders, M.; Wolterbeek, R.; Cransberg, K.; Bruijn, J.A. & Bajema, I.M. (2017), Clinical and Histopathologic Characteristics Associated with Renal Outcomes in Lupus Nephritis, Clinical Journal of the American Society of Nephrology 12(5): 734-743.
- Rijnink, E.C.; Teng, Y.K.O.; Kraaij, T.; Wolterbeek, R.; Bruijn, J.A. & Bajema, I.M. (2017), Idiopathic non-lupus full-house nephropathy is associated with poor renal outcome, Nephrology Dialysis Transplantation 32(4): 654-662.
- Bajema, I.M.; Bruijn, J.A.; Casian, A.; Cid, M.C.; Csernok, E.; Daalen, E. van; Harper, L.; Hauser, T.; Little, M.A.; Luqmani, R.A.; Mahr, A.; Ponte, C.; Salama, A.; Segelmark, M.; Suzuki, K.; Sznajd, J.; Teng, Y.K.O.; Vaglio, A.; Westman, K. & Jayne, D. (2017), The European Vasculitis Society 2016 Meeting Report, Kidney International Reports 2(6): 1018-1031.
- Dam, L.S. van; Kraaij, T.; Kamerling, S.W.; Avramut, M.C.; Jost, C.R.; Koster, A.J.; Scherer, H.U.; Pusey, C.D.; Rabelink, A.J.; Kooten, C. van & Teng, Y.K. (2017), ANCA-ASSOCIATED VASCULITIS- AND SYSTEMIC LUPUS ERYTHEMATOSUS-INDUCED NEUTROPHIL EXTRACELLULAR TRAPS HAVE INTRINSICALLY DIFFERENT FEATURES, Annals of the Rheumatic Diseases 76: 774-774.
- Dam, L. van; Kraaij, T.; Kamerling, S.; Scherer, H.U.; Pusey, C.; Rabelink, T.; Kooten, C. van & Teng, O. (2017), Ex Vivo Induced Neutrophil Extracellular Traps Are Intrinsically Different in Anca-Associated Vasculitis and Systemic Lupus Erythematosus, Arthritis and Rheumatology 69.
- Kraaij, T.; Kamerling, S.W.; Bakker, J.A.; Huizinga, T.W.; Rabelink, T.J.; Kooten, C. van & Teng, Y.K. (2017), SIGNIFICANT REDUCTIONS OF PATHOGENIC AUTOANTIBODIES BY SYNERGETIC RITUXIMAB AND BELIMUMAB TREATMENT EFFECTIVELY INHIBITS NEUTROPHIL EXTRACELLULAR TRAPS IN SEVERE, REFRACTORY SLE - THE SYNBIOSE STUDY, Annals of the Rheumatic Diseases 76: 181-181.
- Kraaij, T.; Kamerling, S.W.; Rooij, E. de; Daele, P.L. van; Bajema, I.; Bredewold, O.W.; Huizinga, T.W.; Rabelink, T.J.; Kooten, C. van & Teng, Y.K. (2017), SYNERGETIC B-CELL IMMUNOMODULATION WITH RITUXIMAB AND BELIMUMAB IS CLINICALLY EFFECTIVE IN SEVERE AND REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS - THE SYNBIOSE PROOF-OF-CONCEPT STUDY, Annals of the Rheumatic Diseases 76: 871-871.
- Schaarenburg, R.A. van; Magro-Checa, C.; Bakker, J.A.; Teng, Y.K.O.; Bajema, I.M.; Huizinga, T.W.; Steup-Beekman, G.M. & Trouw, L.A. (2016), C1q Deficiency and Neuropsychiatric Systemic Lupus Erythematosus, Frontiers in Immunology 7.
- Kraaij, T.; Tengstrom, F.C.; Kamerling, S.W.A.; Pusey, C.D.; Scherer, H.U.; Toes, R.E.M.; Rabelink, T.J.; Kooten, C. van & Teng, Y.K.O. (2016), A novel method for high-throughput detection and quantification of neutrophil extracellular traps reveals ROS-independent NET release with immune complexes, Autoimmunity Reviews 15(6): 577-584.
- Groot, N.; Dijk, W. van; Dolhain, R.J.E.M.; Bijl, M.; Teng, Y.K.O.; Zirkzee, E.J.; Leeuw, K. de; Bultink, I.E.M.; Fritsch-Stork, R.; Kamphuis, S.S.M. & CHILL-NL Study Grp (2016), ADULT OUTCOMES IN A LARGE COHORT OF CHILDHOOD ONSET SLE PATIENTS: FERTILITY AND PREGNANCIES - THE CHILL-NL STUDY, Clinical and Experimental Rheumatology 34(4): S26-S26.
- Berden, A.E.; Beeres, S.L.M.A.; Crobach, S.; Schalij, M.J.; Rabelink, T.J. & Teng, Y.K.O. (2016), Azathioprine-induced eosinophilic myocarditis in a patient with ANCA-associated vasculitis, Clinical and Experimental Rheumatology 34(3): S146-S146.
- Schaarenburg, R.A. van; Magro-Checa, C.; Bakker, J.A.; Teng, Y.K.O.; Bajema, I.M.; Huizinga, T.W.; Steup-Beekman, G.M. & Trouw, L.A. (2016), C1q Deficiency and Neuropsychiatric Systemic Lupus Erythematosus, Frontiers in Immunology 7.
- Kraaij, T.; Kamerling, S.; Rabelink, T.; Toes, R.E.M.; Kooten, C. van & Teng, O. (2015), A High-Throughput System for Quantification of in Vitro Neutrophil Extracellular Trap Formation with Fluorescence Immunocytochemistry, Arthritis and Rheumatology 67.
- Rijnink, E.C.; Reinders, M.; Es, L. van; Teng, O.; Wolterbeek, R.; Bruijn, J. & Bajema, I. (2015), Long-term preserved renal function in class III or IV lupus nephritis without aggressive immunosuppression, Clinical and Experimental Rheumatology 33(3): S32-S32.
- Kraaij, T.; Huizinga, T.W.J.; Rabelink, T.J. & Teng, Y.K.O. (2014), Belimumab after rituximab as maintenance therapy in lupus nephritis, Rheumatology 53(11): 2122-2124.
- Teng, Y.K.O.; Wheater, G.; Hogan, V.E.; Stocks, P.; Levarht, E.W.N.; Huizinga, T.W.J.; Toes, R.E.M. & Laar, J.M. van (2012), Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity, Arthritis Research and Therapy 14(2): -.
- Hogan, V.; Holweg, C.; Kummerfeld, S.; Teng, Y.K.O.; Townsend, M. & Laar, J.M. van (2011), CHANGES IN GENE EXPRESSION IN SYNOVIAL TISSUE FROM REFRACTORY RHEUMATOID ARTHRITIS PATIENTS TREATED WITH RITUXIMAB, Annals of the Rheumatic Diseases 70.
- Wheater, G.; Hogan, V.E.; Teng, Y.K.O.; Tekstra, J.; Tuck, S.P.; Lafeber, F.P.; Huizinga, T.W.; Bijlsma, J.W.; Francis, R.M.; Datta, H.K. & Laar, J. van (2011), SUPPRESSION OF BONE TURNOVER BY B-CELL DEPLETION IN PATIENTS WITH RHEUMATOID ARTHRITIS, Rheumatology 50: 101-101.
- Wheater, G.; Hogan, V.E.; Teng, Y.K.O.; Tekstra, J.; Tuck, S.P.; Lafeber, F.P.; Huizinga, T.W.J.; Bijlsma, J.W.J.; Francis, R.M.; Datta, H.K. & Laar, J.M. van (2010), (PREMIER POSTER-AWARD CANDIDATE) SUPPRESSION OF BONE TURNOVER BY B-CELL DEPLETION IN PATIENTS WITH RHEUMATOID ARTHRITIS, Osteoporosis International 21: S463S463.
- Risselada, A.; Tekstra, J.; Teng, Y.K.; Welsing, P.M.J.; Breedveld, F.; Laar, J.M. van & Bijlsma, J.W.J. (2010), Costs of rituximab maintenance treatment in patients with refractory rheumatoid arthritis, Annals of the Rheumatic Diseases 69(10): 1891U1982.
- Teng YKO, Levarht EWN, Toes REM, Huizinga TWJ & van Laar JM (2009), Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation, Annals of the Rheumatic Diseases 68(6): 1011-1016.
- Bijl, A.E. van der; Teng, Y.K.O.; Oosterhout, M. van; Breedveld, F.C.; Allaart, C.F. & Huizinga, T.W.J. (2009), Efficacy of Intraarticular Infliximab in Patients With Chronic or Recurrent Gonarthritis: A Clinical Randomized Trial, Arthritis and Rheumatism 61(7): 974-978.
- Teng, Y.K.O.; Levarht, E.W.N.; Toes, R.E.M.; Huizinga, T.W.J. & Laar, J.M. van (2009), Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation, Annals of the Rheumatic Diseases 68(6): 1011-1016.
- Teng, Y.K.O.; Tekstra, J.; Breedveld, F.C.; Lafeber, F.; Bijlsma, J.W.J. & Laar, J.M. van (2009), Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: comparison of two B cell depleting treatment strategies, Annals of the Rheumatic Diseases 68(6): 1075-1077.
- Teng, Y.K.O.; Ioan-Facsinay, A. & Laar, J.M. van (2008), CD20 epitope masking by rituximab: comment on the article by Gunnarsson et al, Arthritis and Rheumatism 58(2).
- Teng, Y.K.O.; Engels, M.C. & Laar, Y.M. van (2008), CD22 is not expressed merely on B cells: comment on the article by Vos et al, Arthritis and Rheumatism 58(3).
- Teng, Y.K.O.; Tekstra, J.; Breedveld, F.C.; Lafeber, F.P.; Bijlsma, J.W.J. & Laar, J.M. van (2008), Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: Comparison of two B-cell depleting treatment strategies, Arthritis and Rheumatism 58(9).
- Teng, Y.; Hashemi, M.; Levarht, N.; Bajema, I.; Toes, R.; Huizinga, T. & Laar, J. van (2007), Depleting effects of anti-CD20 monoclonal antibodies in blood, bone marrow and synovium of patients with refractory rheumatoid arhtritis, Annals of the Rheumatic Diseases 66.
- Teng, Y.K.O.; Levarht, E.W.N.; Hashemi, M.; Bajema, I.M.; Toes, R.E.A.; Huizinga, T.W.J. & Laar, J.M. van (2007), Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment, Arthritis and Rheumatism 56(12).
- Gelinck, L.B.S.; Teng, Y.K.O.; Rimmelzwaan, G.F.; Bemt, B.J.F. van den; Kroon, F.P. & Laar, J.M. van (2007), Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab, Annals of the Rheumatic Diseases 66(10).
- Gelinck, L.; Teng, Y.; Rimmelzwaan, G.; Bemt, B. van den; Kroon, F. & Laar, J. van (2007), Poor serological response upon influenza vaccination in patients with rheumatoid arhtritis treated with rituximab, Annals of the Rheumatic Diseases 66.
- Gelinck, L.B.S.; Teng, Y.K.O.; Rimmelzwaan, G.F.; Bemt, B.J.F. van den; Kroon, F.P. & Laar, J.M. van (2007), Poor serological response upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab, Annals of the Rheumatic Diseases 66.
- Teng, Y.; Levarht, N.; Bajema, I.; Toes, R.; Huizinga, T. & Laar, J. van (2007), Recruitment of B lymphocytes into the periphery is associated with disease activity in patients with refractory rheumatoid arthritis, Annals of the Rheumatic Diseases 66.
- Laar, J.M. van; Melchers, M.; Teng, Y.K.O.; Zouwen, B. van der; Mohammadi, R.; Fischer, R.; Margolis, L.; Fitzgerald, W.; Grivel, J.C.; Breedveld, F.C.; Lipsky, P.E. & Grammer, A.C. (2007), Sustained secretion of immunoglobulin by long-lived human tonsil plasma cells, American Journal of Pathology 171(3).
- Teng, Y.K.O.; Verburg, R.J.; Verpoort, K.N.; Zijde, E.C.J.J.V.D.; Huizinga, T.W.J.; Toes, R.E.M.; Breedveld, F.C. & Laar, J.M. van (2006), Proliferating short-lived antibody secreting cells in patients with rheumatoid arthritis are mainly responsible for autoantibody production, Annals of the Rheumatic Diseases 65: 101-102.
- Teng, Y.K.O.; Tilborg, A. van & Laar, J.M. van (2006), Reconstitution of B cells after B cell-depletion therapy: comment on the article by Leandro et al, Arthritis and Rheumatism 54(9).
- Teng, Y.K.O.; Verburg, R.J.; Sont, J.K.; Hout, W.B. van den; Breedveld, F.C. & Laar, J.A. van (2005), Long-term followup of health status in patients with severe rheumatoid arthritis after high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation, Arthritis and Rheumatism 52(8).
- Craen, A.J. de; Gussekloo, J.; Teng, Y.K.O.; Macfarlane, P.W. & Westendorp, R.G.J. (2003), Prevalence of five common clinical abnormalities in very elderly people: population based cross sectional study, British medical journal 327(7407).